Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic
metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be
beneficial for controlling intrahepatic tumour. The investigators aimed to compare the
efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC
patients with EHM.